Cargando…

Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy

The magnitude of the host immune response can be regulated by either stimulatory or inhibitory immune checkpoint molecules. Receptor-ligand binding between inhibitory molecules is often exploited by tumours to suppress anti-tumour immune responses. Immune checkpoint inhibitors that block these inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Zhe, Mowday, Alexandra M., Smaill, Jeff B., Hermans, Ian F., Patterson, Adam V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146304/ https://www.ncbi.nlm.nih.gov/pubmed/33923305 http://dx.doi.org/10.3390/cells10051006

Ejemplares similares

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014)

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress
por: Mowday, Alexandra M., et al.
Publicado: (2016)

Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy
por: Li, Yiliang, et al.
Publicado: (2018)

Hypoxia Potentiates Glioma-Mediated Immunosuppression
por: Wei, Jun, et al.
Publicado: (2011)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3
por: Abbattista, Maria R., et al.
Publicado: (2021)

Hypoxia and oxidative stress in breast cancer: Tumour hypoxia – therapeutic considerations
por: Williams, Kaye J, et al.
Publicado: (2001)

Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications
por: Ashoorzadeh, Amir, et al.
Publicado: (2022)

Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment
por: Miyazaki, Tsubasa, et al.
Publicado: (2020)

The mechanistic immunosuppressive role of the tumour vasculature and potential nanoparticle-mediated therapeutic strategies
por: Ileiwat, Zakaria Elias, et al.
Publicado: (2022)

Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling
por: Jackson-Patel, Victoria, et al.
Publicado: (2022)

Pseudomonas aeruginosa NfsB and nitro-CBI-DEI – a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy
por: Green, Laura K, et al.
Publicado: (2013)

Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy
por: Steingold, Joseph M., et al.
Publicado: (2020)

Cancer immunotherapy by immunosuppression
por: Prehn, Richmond T, et al.
Publicado: (2010)

Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity
por: Bakos, Orneala, et al.
Publicado: (2018)

Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
por: Giles, Amber J., et al.
Publicado: (2018)

Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents
por: Omran, Ziad, et al.
Publicado: (2021)

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials
por: Spiegelberg, Linda, et al.
Publicado: (2019)

Role of the immunosuppressive microenvironment in immunotherapy
por: Tormoen, Garth W., et al.
Publicado: (2018)

Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression
por: Armitage, Jesse D., et al.
Publicado: (2021)

E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications
por: Mowday, Alexandra Marie, et al.
Publicado: (2020)

Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours
por: Young, Kate, et al.
Publicado: (2021)

Tumor-Derived Exosomes in Immunosuppression and Immunotherapy
por: Olejarz, Wioletta, et al.
Publicado: (2020)

The immunosuppressive microenvironment and immunotherapy in human glioblastoma
por: Zhang, Xuehua, et al.
Publicado: (2022)

Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression
por: Finisguerra, Veronica, et al.
Publicado: (2023)

miR25/93 mediates hypoxia-induced immunosuppression by repressing cGAS
por: Wu, Min-Zu, et al.
Publicado: (2017)

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
por: Groth, Christopher, et al.
Publicado: (2018)

Microglia promote glioblastoma via mTOR‐mediated immunosuppression of the tumour microenvironment
por: Dumas, Anaelle A, et al.
Publicado: (2020)

T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases
Publicado: (1981)

Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity
por: Ziani, Linda, et al.
Publicado: (2021)

Hypoxia-driven immunosuppression contributes to the pre-metastatic niche
por: Sceneay, Jaclyn, et al.
Publicado: (2013)

The missing link? LGMN connects hypoxia and immunosuppression in glioblastoma
por: Mitchell, Jonathan, et al.
Publicado: (2023)

Hypoxia-driven protease legumain promotes immunosuppression in glioblastoma
por: Pang, Lizhi, et al.
Publicado: (2023)

Mechanisms of induction of regulatory B cells in the tumour microenvironment and their contribution to immunosuppression and pro-tumour responses
por: Flores-Borja, Fabian, et al.
Publicado: (2022)

Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches
por: Huang, Wen-Juan, et al.
Publicado: (2016)

Tumor neutrophils ferroptosis: a targetable immunosuppressive mechanism for cancer immunotherapy
por: Du, Songtao, et al.
Publicado: (2023)

Immunosuppressive mechanisms of oncofetal reprogramming in the tumor microenvironment: implications in immunotherapy response
por: Currenti, Jennifer, et al.
Publicado: (2023)

Is therapeutic hypothermia immunosuppressive?
por: Polderman, Kees H
Publicado: (2012)

Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development
por: Feng, Jie, et al.
Publicado: (2019)

The role and economics of immunotherapy in solid tumour management
por: Worku, Dominic Adam, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fgenno02a43ujal9qn6ad32j61